← Back to Screener
Dyadic International, Inc. (DYAI)
Price$0.88
Favorite Metrics
Price vs S&P 500 (26W)-25.41%
Price vs S&P 500 (4W)-16.41%
Market Capitalization$31.88M
All Metrics
Book Value / Share (Quarterly)$0.03
P/TBV (Annual)25.52x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)1.79%
Cash Flow / Share (Quarterly)$-0.16
Price vs S&P 500 (YTD)-11.05%
Gross Margin (TTM)24.93%
Net Profit Margin (TTM)-238.31%
EPS (TTM)$-0.24
10-Day Avg Trading Volume0.03M
EPS Excl Extra (TTM)$-0.24
Revenue Growth (5Y)14.07%
EPS (Annual)$-0.23
ROI (Annual)-117.67%
Gross Margin (Annual)24.93%
Net Profit Margin (5Y Avg)-303.18%
Cash / Share (Quarterly)$0.20
Revenue Growth QoQ (YoY)-30.81%
ROA (Last FY)-74.05%
Revenue Growth TTM (YoY)-11.59%
EBITD / Share (TTM)$-0.24
ROE (5Y Avg)-221.45%
Operating Margin (TTM)-232.75%
Cash Flow / Share (Annual)$-0.16
P/B Ratio25.87x
P/B Ratio (Quarterly)27.60x
Net Income / Employee (Annual)$-1
EV / Revenue (TTM)10.45x
Net Interest Coverage (TTM)-32.67x
ROA (TTM)-78.24%
EV / EBITDA (TTM)124.18x
EPS Incl Extra (Annual)$-0.23
Current Ratio (Annual)2.68x
Quick Ratio (Quarterly)2.62x
3-Month Avg Trading Volume0.08M
52-Week Price Return-29.44%
Revenue / Employee (TTM)$1
Tangible BV / Share (Quarterly)$0.02
P/S Ratio (Annual)10.32x
Asset Turnover (Annual)0.31x
52-Week High$1.35
Operating Margin (5Y Avg)-321.89%
EPS Excl Extra (Annual)$-0.23
Tangible BV CAGR (5Y)-31.65%
26-Week Price Return-16.67%
Quick Ratio (Annual)2.62x
13-Week Price Return-0.52%
Total Debt / Equity (Annual)4.08x
Current Ratio (Quarterly)2.68x
Enterprise Value$32.288
Revenue / Share Growth (5Y)10.23%
Asset Turnover (TTM)0.33x
Book Value / Share Growth (5Y)-49.46%
Revenue / Employee (Annual)$1
Inventory Turnover (Annual)3.49x
Pretax Margin (Annual)-238.31%
Cash / Share (Annual)$0.20
3-Month Return Std Dev75.67%
Gross Margin (5Y Avg)33.88%
Net Income / Employee (TTM)$-1
ROE (Last FY)-597.58%
Net Interest Coverage (Annual)-32.67x
EPS Basic Excl Extra (Annual)$-0.23
P/FCF (TTM)21.99x
Receivables Turnover (TTM)4.66x
Total Debt / Equity (Quarterly)4.08x
EPS Incl Extra (TTM)$-0.24
Receivables Turnover (Annual)4.66x
ROI (TTM)-84.44%
P/S Ratio (TTM)10.32x
Pretax Margin (5Y Avg)-303.18%
Revenue / Share (Annual)$0.09
Tangible BV / Share (Annual)$0.06
Price vs S&P 500 (52W)-64.53%
Year-to-Date Return-6.91%
5-Day Price Return1.83%
EPS Normalized (Annual)$-0.23
ROA (5Y Avg)-69.53%
Net Profit Margin (Annual)-238.31%
Month-to-Date Return6.71%
EBITD / Share (Annual)$-0.22
Operating Margin (Annual)-232.75%
LT Debt / Equity (Annual)4.08x
ROI (5Y Avg)-94.03%
LT Debt / Equity (Quarterly)4.08x
EPS Basic Excl Extra (TTM)$-0.24
P/TBV (Quarterly)84.50x
P/B Ratio (Annual)27.60x
Inventory Turnover (TTM)0.51x
Pretax Margin (TTM)-238.31%
Book Value / Share (Annual)$0.03
Price vs S&P 500 (13W)-3.39%
Beta1.30x
P/FCF (Annual)6.80x
Revenue / Share (TTM)$0.11
ROE (TTM)-350.86%
52-Week Low$0.65
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.14
4.14
4.14
4.14
Industry Peers — Biological Products(88)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
DYAIDyadic International, Inc. | 10.32x | -11.59% | 24.93% | — | $0.88 |
AMGNAmgen Inc | 5.20x | 9.95% | 73.30% | 2.93% | $350.16 |
GILDGilead Sciences Inc | 5.71x | 2.40% | 78.83% | 133.64% | $135.87 |
ARGXargenx SE American Depositary Shares | 12.59x | 89.56% | 150.91% | — | $834.45 |
BNTXBioNTech SE American Depositary Share | 9.06x | -11.81% | 84.21% | — | $105.19 |
BIIBBiogen Inc. Common Stock | 2.72x | 2.22% | 75.69% | -18.77% | $183.34 |
MRNAModerna, Inc. Common Stock | 10.91x | -39.93% | 70.32% | — | $54.59 |
NBIXNeurocrine Biosciences Inc | 4.64x | 21.45% | 98.18% | 2.31% | $131.59 |
EXELExelixis Inc | 4.89x | 6.85% | 96.39% | 31.10% | $43.61 |
TECHBio-Techne Corp. | 7.72x | 1.64% | 66.60% | -20.58% | $60.58 |
IBRXImmunityBio, Inc. Common Stock | 74.42x | 668.31% | 99.34% | — | $8.20 |
About
Dyadic International is a biotechnology company that develops and licenses a gene expression platform based on the C1 fungus (Thermothelomyces heterothallica) for producing industrial enzymes and proteins. The company generates recurring revenue through technology licensing agreements with major industrial partners including BASF, Abengoa Bioenergy, and Codexis for non-pharmaceutical applications.